Metabolomics vs Genetics: Looking Beyond Inherited Risk

For decades, predicting Alzheimer’s disease has meant reading a person’s genetic code. Genomics, brain imaging, and biomarker research have transformed how scientists understand neurodegeneration, allowing clinicians to spot disease-related changes years before symptoms surface. But according to Dr. James (Chia-Chu) Tsai, founder and CEO of Homnia, all of that inherited data still misses something essential: what’s actually happening inside the body right now.

“Genetics tells you about risk,” he said. “But risk is not the same as biology.”

Metabolomics and the Future of Longevity Prediction

As healthcare shifts from treating disease toward extending healthspan—the years people remain healthy and independent—that distinction matters more than ever. Genetic testing can estimate inherited susceptibility to Alzheimer’s and other chronic illnesses, but it can’t capture how decades of nutrition, sleep, stress, exercise, and environmental exposure have shaped an individual’s health. Tsai believes decoding those biological changes may become one of precision medicine’s defining challenges.

At the center of his approach is metabolomics: the large-scale analysis of small molecules circulating through the body. Unlike DNA, which stays largely fixed for life, metabolites shift continuously, reflecting inflammation, mitochondrial function, hormone regulation, and dozens of other physiological processes in real time.

“I like to compare genetics to the map you’re given at birth,” Tsai explained. “It shows where the mountains are and where the valleys are. Metabolomics is your GPS. It tells you where you are today—and whether you’re moving toward healthier biology or whether the ground beneath you is already beginning to slide.”

For Tsai, metabolomics isn’t just another biomarker platform—it’s a shift from predicting inherited probability to tracking biological direction while there’s still time to change course.

Understanding Biological Trajectory

Polygenic risk scores (PRS) have become central to predictive medicine, combining thousands of genetic variants to estimate disease susceptibility. Tsai sees real value in these models, but argues they tell only part of the story.

“PRS tells you what genetic cards you were dealt,” he said. “Metabolomics tells you how those cards are actually being played.”

Every biological process—nutrient metabolism, immune signaling, hormone regulation, mitochondrial energy production—leaves a signature in the body’s metabolite profile, shaped by genes, lifestyle, gut microbiota, and aging combined.

“Our cells are constantly speaking through metabolites,” Tsai said. “They’re the biochemical language of the body.”

That’s why two people with identical genetic risk can end up in very different places. One might preserve healthy metabolism through favorable habits, delaying disease despite elevated inherited risk. Another might accumulate inflammation and metabolic dysfunction, accelerating biological aging even with modest genetic susceptibility.

“The genes don’t change,” Tsai said. “Your metabolism does. And because metabolism changes, it’s something we can potentially influence.”

The Biology Behind Healthy Longevity

Tsai doesn’t see Alzheimer’s as an isolated neurological condition, but as one manifestation of a broader biological process shared across chronic disease.

“We often think of disease as a single event,” he said. “In reality, it’s usually the result of years—even decades—of accumulated biological change.”

That thinking shapes Homnia’s approach. Rather than focusing narrowly on earlier Alzheimer’s diagnosis, the company treats metabolomics as a platform for understanding biological aging itself—with Alzheimer’s as the first application of a much broader ambition.

Using high-resolution LC-MS/MS mass spectrometry, Homnia’s platform measures more than 2,000 metabolites from a single blood sample, offering insight into mitochondrial function, lipid metabolism, inflammation, and neurotransmitter synthesis. Alzheimer’s pathology can begin ten to twenty years before measurable cognitive decline—and during much of that silent window, metabolic profiles have already begun to shift.

“For years we’ve studied the consequences of Alzheimer’s disease,” he said. “We’ve discovered amyloid plaques, tau pathology, and brain atrophy. But the bigger question is what caused those changes in the first place.”

“The exciting part isn’t simply predicting disease,” Tsai said. “It’s identifying those biological clues while they’re still reversible.”

As healthcare shifts from treating disease to preserving healthspan, emerging technologies are helping clinicians identify biological changes years before symptoms appear. Image: GeneOnline

From Prediction to Precision Prevention

Prediction alone, however, has limited value if there’s no way to act on it—something Tsai considers one of predictive medicine’s biggest blind spots.

“Prediction without intervention,” he said, “is just another diagnosis.”

Because metabolism responds to nutrition, activity, sleep, and supplementation, clinicians can track whether biology is genuinely improving over time, rather than simply flagging static risk.“Most chronic diseases develop gradually,” Tsai said. “If disease develops over many years, maintaining health also has to be a long-term process. You need tools that tell you what has changed, where the imbalance is, and whether your interventions are actually working.”

“The goal isn’t to give everyone the same advice,” he said. “It’s to understand what this individual body needs.”

Measuring Prevention Through Metabolomics

Preventive medicine’s hardest problem isn’t identifying risk—it’s proving prevention works. Demonstrating that someone avoided Alzheimer’s because of an early intervention is far harder than showing a measurable treatment response, and Tsai understands why many clinicians remain cautious.

“Medicine has traditionally been built around symptoms,” he said. “You diagnose a disease, then you treat it. Prevention asks a very different question: what should we do before disease becomes visible?”

He sees a natural divide forming: physicians in functional medicine, endocrinology, and preventive health tend to intervene earlier when markers drift, while others wait for stronger clinical evidence—caution he considers scientifically justified.

“The science isn’t finished,” he said. “We shouldn’t pretend otherwise.”

Still, he argues that waiting for perfect evidence has its own cost. If abnormalities are detectable now, postponing action until trials conclude may mean losing the disease’s most reversible window. Metabolomics offers shorter-term, measurable endpoints instead—shifts in mitochondrial function, inflammatory pathways, and lipid metabolism that can be tracked as interventions unfold.

“The body gives us feedback,” Tsai said. “Biology is measurable. If metabolism changes, we can see it.”

From Generic Wellness to Personalized Longevity

Measuring biology this precisely also changes how prevention gets delivered. General advice—exercise more, eat better, sleep well—remains broadly true but rarely specific.

“General advice isn’t wrong,” Tsai said. “It’s simply not specific enough.”

Homnia’s data suggests metabolomic profiles often reveal more about a person’s lifestyle than expected—alcohol consumption, dietary patterns, and nutritional deficiencies all leave measurable signatures in the blood.

“It’s almost like fortune telling,” Tsai joked. “Except we’re not predicting fate—we’re reading metabolism.”

Those signatures let interventions become genuinely individualized: resistance training over cardio for one person, omega-3 or mitochondrial support for another. “The same lifestyle doesn’t produce the same biology in everyone,” Tsai said. “That’s why prevention also has to be personalized.”

AI, Digital Twins, and the Future of Precision Health

Collecting biological data is only half the challenge—making it usable is the other half.

“A laboratory report full of numbers doesn’t change behaviour,” Tsai said. “People don’t need more data. They need someone to explain what the data actually means.”

That’s driving Homnia’s broader vision: an AI-powered platform integrating metabolomic profiles with medical history, medications, and lifestyle data into a continuously updated “digital twin” of a person’s health.

“We have many AI systems that can answer health questions,” he said. “But they don’t know you.”

He imagines people consulting a personal AI health companion before traveling, managing illness, or adjusting nutrition—grounded not in generic advice, but in their own metabolic status, allergies, and history.“The role of AI isn’t to replace physicians,” Tsai said. “It’s to become a translator.”

“Science has to speak human language,” he added. “If people don’t understand their biology, they can’t act on it.”

From Disease Prediction to Healthy Longevity

Although Homnia began with Alzheimer’s, Tsai views it as one application of a much larger platform. Pathways like mitochondrial dysfunction, inflammation, and lipid metabolism cut across cardiovascular disease, type 2 diabetes, and biological aging broadly—meaning the same tools could extend far beyond neurodegeneration.

“Our goal isn’t simply to predict Alzheimer’s disease,” he said. “It’s to help people maintain health for longer.”

That reflects a larger shift in healthcare: as populations age, extending lifespan alone isn’t enough—preserving healthspan matters just as much. “Good health isn’t luck,” Tsai said. “It’s the result of informed choices.”

Whether metabolomics becomes a routine part of preventive care will depend on continued clinical validation. But its promise reaches beyond flagging disease risk—it offers a dynamic view of how health evolves, and how that trajectory might still be changed.

“In the past, medicine focused on treating disease after it appeared,” Tsai reflected. “The future is about recognizing biological change while people still have the opportunity to choose a different path.” In that future, genetics may explain where we began. Metabolomics may show where we’re actually going.

Dr. James (Chia-Chu) Tsai (featured), founder and CEO of Homnia Inc., advocates for a shift from measuring inherited risk alone to understanding the body’s real-time biology, enabling more proactive and personalized approaches to preventive healthcare.

Author

Bernice Lottering